23andMe Holding Co. is a genetic testing and biotechnology company that provides direct-to-consumer DNA testing services. The company was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. The name "23andMe" refers to the 23 pairs of chromosomes found in human DNA.
The company's main offering is its personal genetic testing kit, which allows individuals to uncover information about their ancestry, health predispositions, carrier status for certain genetic conditions, and traits. Customers provide a saliva sample, which is then analyzed in the company's laboratory to generate reports and insights based on their genetic data.
One of the key features of 23andMe's service is its emphasis on consumer empowerment and personalized health information. By providing access to genetic data, the company aims to enable individuals to make more informed decisions about their health and well-being. This includes understanding genetic risks, exploring ancestry and genealogy, and contributing to research studies.
23andMe became a publicly traded company through a merger with VG Acquisition Corp in 2021. Following the merger, the company is now listed on the Nasdaq Global Select Market under the ticker symbol "ME." The move to go public has provided additional resources and opportunities for the company to expand its offerings and accelerate its research and development efforts.
Besides its direct-to-consumer genetic testing service, 23andMe has also collaborated with pharmaceutical companies and researchers to conduct genetic research. Through its research platform, 23andMe has collected a vast amount of genetic data, making it a valuable resource for studies related to various health conditions and traits. The company has undertaken initiatives to contribute to scientific advancements and drive innovation in the field of genetics.